Hormone-naive, or ‘castrate sensitive’ advanced prostate cancer (CSPC) is characterized by non-castrate testosterone levels and includes clinical disease states ranging from patients with prostate specific antigen (PSA) recurrence to those patients with metastatic prostate cancer detected by imaging. This evidence concerns the gene KLK3 and prostate carcinoma.